UNICOCELL BIOMED continues to advance development of its allogeneic stem cell drug candidate ELIXCYTE, targeting the aging population. In addition to nearing completion of patient enrollment for its Phase III trial in osteoarthritis this year, the company also expects to initiate a Phase III trial for chronic kidney disease (CKD) within the year, with several other indications in active development. The management team stated that both major indications meet the addendum criteria under Taiwan’s dual regenerative medicine regulations, creating opportunities for early market entry. The company is also engaged in ongoing domestic and international out-licensing discussions. Meanwhile, its CDMO services have started bearing fruit, with exosome-based applications entering the haircare market and future plans to expand into regenerative medicine. The company’s transition from the Innovation Board to the Main Board is currently underway.
UNICOCELL BIOMED held an investor conference on June 4 to present updates on its liquid stem cell drug pipeline, commercialization of its exosome products, 2024 financial performance, cell bank resource planning, CDMO business development, and licensing strategies.
General Manager Yi-Pei Hung stated that patient enrollment for the Phase III osteoarthritis trial is progressing as planned. For the CKD program, the company has completed its Phase II trial report and submitted it to both the U.S. FDA and Taiwan’s TFDA. It plans to initiate regulatory consultations for the next phase of clinical trial design in the near future.
Combined, the two indications represent a potential patient population of over five million in Taiwan—more than three million for knee osteoarthritis and over two million for chronic kidney disease. On a global scale, the market is even larger. For instance, according to GlobalData, the global osteoarthritis treatment market is projected to exceed USD 1.2 billion by 2030. Meanwhile, cell therapy for CKD remains a largely untapped niche, especially in pre-dialysis intervention, positioning it as a potential breakthrough area for new cell therapies.
Both indications are eligible for early market entry in Taiwan under the provisions of the regenerative medicine legislation, providing a potential source of revenue for the company. Preliminary internal estimates suggest that after official launch, based on experience from self-pay treatments approved under the Special Regulation framework, an initial annual penetration rate of 0.05% could be achieved—equivalent to approximately 2,000 treated patients annually. With future inclusion in the national health insurance system and optimized pricing strategies, this rate could grow significantly.
Regarding pricing strategy, UNICOCELL BIOMED intends to benchmark against existing regenerative therapies on the market—such as hyaluronic acid injections, PRP therapy, and artificial joint replacements—to develop a pricing model that balances patient affordability with production costs. For the CKD program, the company will consider Taiwan’s National Health Insurance expenditure structure, using the average annual cost of NT$570,000 per patient as a basis to evaluate pricing feasibility and market acceptance for the cell therapy.
Beyond knee osteoarthritis and CKD, the company is actively developing additional applications for age-related degenerative conditions, including ocular degeneration, glaucoma, and retinal diseases—targeting future indications such as macular degeneration and dry eye syndrome. Other development directions include chronic wounds, Parkinson’s disease, and frailty-related aging disorders, all of which represent promising areas for stem cell and stem cell-derived product applications.
UNICOCELL BIOMED’s 2024 operating income is driven by three main areas: revenue from clinical and R&D collaborations for its cell therapies, CDMO services for allogeneic cell products, and commercialization of its exosome products. Revenue has shown steady growth—from NT$24 million in 2023, to NT$31 million in 2024, and NT$9.8 million in the first quarter of this year. Current assets grew from NT$59 million at the end of 2024 to NT$68 million in the first quarter of 2025, with net asset value per share at NT$12.86.
Additionally, the company’s stem cell-derived exosome products have received INCI cosmetic ingredient certifications in Japan and internationally, and have already been sold in multiple countries. UNICOCELL recently entered into a formal partnership with the MANDOO Group, integrating its exosome formulations into the group’s salon systems as part of a dedicated hair care treatment program, officially launching on the consumer market. This marks Taiwan’s first exosome-based haircare product. The company plans to expand exosome applications from cosmetic ingredients to include regenerative medicine formulations and clinical uses.
Regarding its anticipated listing transfer, the management team confirmed that under Innovation Board rules, companies are eligible to apply for Main Board transfer after one full year of listing. Preparation for the application is already underway. On the licensing front, UNICOCELL is in discussions with several international consultants and potential partners, with prospects for regional licensing and co-development agreements to expand its global footprint.
Resource: 向榮生醫-創異體細胞新藥雙適應症續推進，創新版轉一般板進行中
